Loading…
Loading…
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.
NEW YORK, July 20, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Erik Schneberger as Executive Vice President, Chief Marketing Officer. Based in New York, Mr.
Cohen & Steers, Inc. is now rated Hold after a strong rally closed the prior valuation gap. CNS's Q2 saw net inflows of $1.3B and AUM rise to $100.1B, signaling renewed interest in public real estate. Operating margin expanded to 36.3% on revenue growth, with scope to reach 37% in H2 if markets remain stable.
Cohen & Steers, Inc. (CNS) Q2 2026 Earnings Call Transcript
Cohen & Steers NYSE: CNS reported higher second-quarter 2026 adjusted earnings and assets under management, as executives pointed to improving demand for real estate, infrastructure, preferred securities and broader real assets strategies.
NEW YORK, July 16, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended June 30, 2026. The earnings release along with the accompanying earnings presentation can be viewed at Cohen & Steers Reports Results for Second Quarter 2026 and on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive.
NEW YORK, July 16, 2026 /PRNewswire/ -- Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") today announced the results of its transferable rights offering (the "Offer"), which commenced on June 18, 2026 and expired on July 15, 2026 (the "Expiration Date"). The Offer was led by UBS Investment Bank as the sole dealer manager.
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for CNS and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.